The FDA approves Eli Lilly’s (NYSE:LLY)
Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL),
a rapid-acting insulin to improve glycemic control in type 1 and type 2
diabetics.
The product will be included in the Lilly Insulin
Value Program that allows patients to fill their monthly prescriptions
for $35.
https://seekingalpha.com/news/3583304-fda-oks-lilly-fast-acting-insulin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.